Literature DB >> 1641272

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

R L Henry1, C M Mellis, L Petrovic.   

Abstract

The aim of this study was to assess the prognostic significance of mucoid and non-mucoid isolates of Pseudomonas aeruginosa (muPs and non-muPs) from the sputa of patients with cystic fibrosis (CF). Eighty-one children with CF who coughed up sputum daily were recruited and followed over 12 months with frequent sputum cultures. At the end of this observation period they were classified to one of three age-matched groups. In 50 mPs was isolated on one or more occasions; 19 grew non-muPs but not muPs, and 12 grew no isolates of Ps aeruginosa. These 81 children and adolescents were followed for a further 8 years or until they died. Twenty-one (42%) of the muPs patients died compared with two (11%) of the non-muPs and one (8%) of the no Ps patients (P less than 0.01). Stepwise regression indicated that forced expiratory volume in 1 second (FEV1) had the main predictive effect but that age, Shwachman score and muPs also had a predictive effect. Identification of mucoid forms of Ps aeruginosa is an unfavorable prognostic factor but the isolation of non-mucoid strains does not appear to be any more important than the isolation of other common respiratory pathogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641272     DOI: 10.1002/ppul.1950120306

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  122 in total

Review 1.  Cystic fibrosis.

Authors:  P Robinson
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

Review 2.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

3.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

4.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

5.  Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.

Authors:  Olanrewaju O Okusanya; Sujata M Bhavnani; Jeffrey P Hammel; Alan Forrest; Catharine C Bulik; Paul G Ambrose; Renu Gupta
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

7.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

8.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.

Authors:  Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  ATP7B detoxifies silver in ciliated airway epithelial cells.

Authors:  Aida Ibricevic; Steven L Brody; Wiley J Youngs; Carolyn L Cannon
Journal:  Toxicol Appl Pharmacol       Date:  2009-12-11       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.